Development of an α-Synuclein Amyloid Tracer

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a peptide with a specific amino acid sequence (SEQ ID NO: 1) that can be used as an amyloid tracer for alpha-synuclein. It is intended for use in the diagnosis and treatment of synucleinopathies, which are diseases characterized by abnormal accumulation of alpha-synuclein protein, such as Parkinson's disease.

Use CasesContent extracted from patent full text and abstract with AI.

• Medical imaging to detect alpha-synuclein in brain tissues for early diagnosis of Parkinson’s disease and other synucleinopathies.
• Therapeutic applications aimed at targeting or removing alpha-synuclein aggregates in neurodegenerative disorders.
• Research tool for studying disease progression and the role of alpha-synuclein in neurodegenerative conditions.
• Potential use in drug development to screen compounds for efficacy in reducing amyloid accumulation.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables earlier and more accurate diagnosis of synucleinopathies such as Parkinson's disease.
• Facilitates monitoring of disease progression and treatment response in patients.
• May contribute to the development of new therapies targeting alpha-synuclein aggregates.
• Provides a specific and targeted approach compared to general amyloid tracers, possibly reducing false positives.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Described is a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 as well as such a peptide for use in the treatment of synucleinopathies.